Correction of anemia in uremic rats by intramuscular injection of lentivirus carrying an erythropoietin gene

American Journal of Nephrology

Volumn 26, Issue 4, 2006, Pages 326-334

  Tae, Keun Oh ^a   Gui, Hong Quan ^b   Hae, Young Kim ^a   Park, Frank ^c   Seung, Taik Kim ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b YANBIAN UNIVERSITY   (China)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Erythropoietin; Gene therapy; Lentiviral vector; Partial nephrectomy; Uremic rats

Indexed keywords

BETA GALACTOSIDASE; ERYTHROPOIETIN; LENTIVIRUS VECTOR;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; ENZYME ASSAY; ERYTHROCYTE; GENE THERAPY; HEMATOCRIT; MALE; NEPHRECTOMY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UREMIA;

ANEMIA; ANIMALS; ERYTHROPOIETIN; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INJECTIONS, INTRAMUSCULAR; KIDNEY FAILURE, CHRONIC; LENTIVIRUS; MALE; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME; UREMIA;

EID: 33748702530     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094401     Document Type: Article

References (31)

1. Koury MJ, Bondurant MC: The molecular mechanism of erythropoietin action. Eur J Biochem 1992;210:649-663.
2. Goodnough LT, Skikne B, Brugnara C: Erythropoietin, iron, and erythropoiesis. Blood 2000;96:823-833.
3. Lejnieks DV, Ramesh N, Lau S, Osborne WRA: Stomach implant for long-term erythropoietin expression in rats. Blood 1998;3:888-893.
4. Einbinder T, Sufaro Y, Yusim I, Byk G, Passlick-Deetjen J, Chaimovitz C, et al: Correction of anemia in uremic mice by genetically modified peritoneal mesothelial cells. Kidney Int 2003;63:2103-2112.
5. Osada S, Ebihara I, Setoguchi Y, Takahashi H, Tomino Y, Koide H: Gene therapy for renal anemia in mice with polycystic kidney using an adenovirus vector encoding the human erythropoietin gene. Kidney Int 1999;55:1234-1240.
6. Lippin Y, Dranitzki-Elhalel M, Brill-Aimon E, Mei-Zahav C, Mizrachi S, Niberman Y, et al: Human erythropoietin gene therapy for patients with chronic renal failure. Blood 2005;106:2280-2286.
7. Rivera VM, Gao G, Grant RL, Schnell MA, Zoltick PW, Rozamus LW, et al: Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 2005;105: 1424-1430.
8. Seppen J, Barry SC, Harder B, Osborne WRA: Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin. Blood 2001;98:594-596.
9. Tripathy SK, Svensson EC, Black HB, Goldwasser E, Margalith M, Hobart PM, et al: Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci USA 1996;93:10876-10880.
10. Maruyama H, Sugawa M, Moriguchi Y, Imazeki I, Ishikawa Y, Ataka K, et al: Continuous erythropoietin delivery by muscle-targeted gene transfer using in vivo electroporation. Hum Gene Ther 2000;11:429-437.
11. Maruyama H, Ataka K, Gejyo F, Higuchi N, Ito Y, Hirahara H, et al: Long-term production of erythropoietin after elctroporation-mediated transfer of plasmid DNA into the muscle of normal and uremic rats. Gene Ther 2001;8:461-468.
12. Rizzuto G, Cappelletti M, Mennuni C, Wiznerowicz M, DeMartis A, Maione D, et al: Gene electrotransfer results in a high-level transduction of rat skeletal muscle and corrects anemia of renal failure. Hum Gene Ther 2000;11:1891-1900.
13. Ataka K, Maruyama H, Neichi T, Miyazaki J, Gejyo F: Effects of erythropoietin-gene electrotransfer in rats with adenine-induced renal failure. Am J Nephrol 2003;23:315-323.
14. Hammamori Y, Samal B, Tian J, Kedes L: Myoblast transfer of human erythropoietin gene in a mouse model of renal failure. J Clin Invest 1995;95:1808-1813.
15. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage HF, et al: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-267.
16. Corbeau P, Kraus G, Wong-Staal F: Efficient gene transfer by a human immunodeficiency virus type 1(HIV-1)-derived vector utilizing a stable HIV packaging cell line. Proc Natl Acad Sci USA 1996;93:14070-14075.
17. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM: Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997;17:314-317.
18. Zufferey R, Dull T, Mendal RJ, Bukovsky A, Quiroz D, Naldini L, et al: Self-inactivating lentivirus vector for safe efficient in vivo gene delivery. J Virol 1998;72:9873-9880.
19. + cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999;283:682-686.
20. Blomer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH: Highly efficient and sustained gene transfer in adult neurons with lentivirus vector. J Virol 1997;71:6641-6649.
21. - human hematopoietic cells by HIV-1 based lentiviral vectors. Proc Natl Acad Sci USA 1999;96:2988-2993.
22. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al: A third-generation lentivirus vector with a conditional packaging system. J Virol 1998;72:8463-8471.
23. Oh TK, Li MZ, Kim ST: Gene therapy for diabetes mellitus in rats by intramuscular injection of lentivirus containing insulin gene. Diabetes Res Clin Pract 2006;71:233-240.
24. Chanutin A, Ferris JEB: Experimental renal insufficiency produced by partial nephrectomy. Arch Intern Med 1932;49:767-787.
25. Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR, et al: Effects of recombinant human erythropoietin on renal function in chronic renal failure in predialysis patients. Am J Kidney Dis 1994;24:777-784.
26. Valderrabino F: Erythropoietin in chronic renal failure. Kidney Int 1996;50:1373-1391.
27. Markham A, Bryson HM: Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs 1995;49:232-254.
28. McDonald TP, Clift R, Cottrell MB: Large, chronic doses of erythropoietin cause thrombocytopenia in mice. Blood 1992;80:352-358.
29. Manilla P, Afable C, Slepushkin V, Humeau LM, Schonely K, Ni Y, et al: Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther 2005;16:17-25.
30. + infected patients grouped according to CD4 count and viral load. Mol Ther 2004;9:902-913.
31. Bank A, Dorazio R, Leboulch P: A phase I/II clinical trial of β-globin gene therapy for β-thalassemia. Ann NY Acad Sci 2005;1054:308-316.